Solve this question paper. Use latest medical guidelines and evidences. Don't write long sentances. Give maximum answers in tables, flowchart and diagrams
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Searching the Web
INTERLACE trial CALLA trial locally advanced cervical cancer 2024 results
Searching PubMed
cancer prehabilitation ovarian cancer cytoreductive surgery
Reading File
Searching the Web
CALLA trial locally advanced cervical cancer anlotinib chemoradiotherapy results 2024
Searching PubMed
immunotherapy pembrolizumab gestational trophoblastic neoplasia treatment
All 10 questions answered. Here's a quick summary of key updates from latest guidelines used:
Key High-Yield Points for This Paper
| Q | Most Important Point |
|---|---|
| Q1 | NECC in pregnancy: use PE regimen (Cisplatin+Etoposide) NOT standard regimens; CCRT after delivery |
| Q2 | PI3K-AKT-mTOR + PARP pathways are the most actionable in gyn oncology |
| Q3 | WT1 + PAX8 = HGSC; CDX2 + CK20 = GI metastasis (Krukenberg) |
| Q4 | Uterine artery crossing = most common site of ureteric injury (75%); always spatulate + stent |
| Q5 | Prehab = multimodal: exercise + nutrition + psychosocial + anemia Rx; start 3-6 weeks before CRS |
| Q6 | Meijer criteria: ≥90% sensitivity / ≥98% specificity vs HC2; genotyping (16/18) guides triage |
| Q7 | INTERLACE = POSITIVE (carbo+taxol induction before CCRT); CALLA = NEGATIVE (durvalumab failed) |
| Q8 | EMA-CO for high-risk GTN; pembrolizumab for chemo-resistant/refractory GTN |
| Q9 | Gracilis = Type II (medial femoral circumflex); VRAM = Type III (DIEA) - both key for vulvar reconstruction |
| Q10 | LACC Trial: MIS radical hysterectomy is inferior to open - do NOT do MIS radical Hx for cervical cancer |
This is a shared conversation. Sign in to Orris to start your own chat.